ES2704704T3 - Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden - Google Patents

Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden Download PDF

Info

Publication number
ES2704704T3
ES2704704T3 ES14869323T ES14869323T ES2704704T3 ES 2704704 T3 ES2704704 T3 ES 2704704T3 ES 14869323 T ES14869323 T ES 14869323T ES 14869323 T ES14869323 T ES 14869323T ES 2704704 T3 ES2704704 T3 ES 2704704T3
Authority
ES
Spain
Prior art keywords
compound
formula
mmol
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14869323T
Other languages
English (en)
Spanish (es)
Inventor
Changsik Lee
Hyun-Mo Yang
Changkon Lee
Miseon Bae
Soyoung Kim
Youngil Choi
Nina Ha
Jaekwang Lee
Jungtaek Oh
Hyeseung Song
Ilhyang Kim
Daekyu Choi
Jaeki Min
Hyojin Lim
Daekwon Bae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Application granted granted Critical
Publication of ES2704704T3 publication Critical patent/ES2704704T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES14869323T 2013-12-12 2014-12-12 Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden Active ES2704704T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130154455 2013-12-12
PCT/IB2014/002768 WO2015087151A1 (en) 2013-12-12 2014-12-12 Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
ES2704704T3 true ES2704704T3 (es) 2019-03-19

Family

ID=53370682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14869323T Active ES2704704T3 (es) 2013-12-12 2014-12-12 Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden

Country Status (12)

Country Link
US (1) US9650379B2 (cg-RX-API-DMAC7.html)
EP (1) EP3080125B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016540024A (cg-RX-API-DMAC7.html)
KR (1) KR101689394B1 (cg-RX-API-DMAC7.html)
CN (1) CN105940001B (cg-RX-API-DMAC7.html)
DK (1) DK3080125T3 (cg-RX-API-DMAC7.html)
ES (1) ES2704704T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181965T1 (cg-RX-API-DMAC7.html)
PL (1) PL3080125T3 (cg-RX-API-DMAC7.html)
PT (1) PT3080125T (cg-RX-API-DMAC7.html)
TR (1) TR201900057T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015087151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157504A1 (en) 2014-04-11 2015-10-15 Taipei Medical University Histone deacetylase inhibitors
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
BR112017027798B1 (pt) 2015-07-27 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HRP20230052T1 (hr) 2015-07-27 2023-03-03 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20200041812A (ko) * 2018-10-12 2020-04-22 주식회사 종근당 히스톤 탈아세틸화 효소 억제제 및 메토트렉세이트를 포함하는 약학적 조성물
CN113874369B (zh) 2019-05-31 2024-08-27 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
TWI908740B (zh) * 2019-10-09 2025-12-21 美商百歐克斯製藥公司 口服補體因子d抑制劑
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof
CN115417877B (zh) * 2022-09-20 2024-05-14 杭州师范大学 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
BRPI0817897A2 (pt) * 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
MX2010006243A (es) * 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
KR101168801B1 (ko) 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
JP5838157B2 (ja) 2009-07-22 2015-12-24 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイThe Board Of Trustees Of The University Of Illinois Hdac阻害剤およびそれを用いる治療法
USRE47009E1 (en) * 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2012178208A2 (en) * 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2013052110A1 (en) * 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2013062344A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
EP2785720B1 (en) 2011-11-29 2017-08-09 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents

Also Published As

Publication number Publication date
KR20150068923A (ko) 2015-06-22
PT3080125T (pt) 2018-12-14
WO2015087151A1 (en) 2015-06-18
EP3080125A4 (en) 2017-08-02
JP2016540024A (ja) 2016-12-22
JP6561167B2 (ja) 2019-08-14
HRP20181965T1 (hr) 2019-02-08
KR101689394B1 (ko) 2016-12-23
PL3080125T3 (pl) 2019-06-28
TR201900057T4 (tr) 2019-01-21
CN105940001B (zh) 2018-02-06
DK3080125T3 (en) 2019-01-07
JP2018109068A (ja) 2018-07-12
EP3080125A1 (en) 2016-10-19
US9650379B2 (en) 2017-05-16
EP3080125B1 (en) 2018-10-10
CN105940001A (zh) 2016-09-14
US20160289230A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
JP6561167B2 (ja) 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物
AU2017395023B2 (en) Compounds and methods for CDK8 modulation and indications therefor
JP7041198B2 (ja) Jak阻害剤である5-クロロ-2-ジフルオロメトキシフェニルピラゾロピリミジン化合物
TWI896747B (zh) 快速加速纖維肉瘤蛋白質降解之化合物及包含其之組成物
JP6779992B2 (ja) N−スルホニル化ピラゾロ[3,4−b]ピリジン−6−カルボキサミドおよび使用法
CN114650868A (zh) Helios的小分子降解剂及其使用方法
CN102015705B (zh) 稠合的杂环衍生物及其用途
EP3846800A1 (en) Compounds for the degradation of brd9 or mth1
CN114867727A (zh) Tau蛋白靶向化合物及相关使用方法
CA3202355A1 (en) Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
ES2583528T3 (es) Compuesto de pirazoloquinolina
KR20180058832A (ko) Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
JP2019509978A (ja) Rock阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
CA3031073A1 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
JP2025523393A (ja) 二環式置換グルタルイミドセレブロンバインダー
KR20240109977A (ko) Kif18a의 스피로 인돌린 억제제
CA2789408A1 (en) Pyrazolo piperidine derivatives as nadph oxidase inhibitors
WO2013117645A1 (en) Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
CA3189873A1 (en) 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis
KR102682398B1 (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2021032323A1 (en) Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
CA3199333A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
CN105985354B (zh) 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
CN116940571A (zh) 苯并异噁唑衍生物及其用途
CN117062814A (zh) 快速加速纤维肉瘤蛋白降解的化合物和相关使用方法